Augmentation strategies in depression 2000

Journal of Clinical Psychiatry

Volumn 61, Issue SUPPL. 2, 2000, Pages 13-19

  Nelson, J Craig ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; DEXAMPHETAMINE; FLUOXETINE; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PINDOLOL; RESERPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; TRYPTOPHAN; YOHIMBINE; ZIMELDINE;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; HUMAN; HUMAN TISSUE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BUSPIRONE; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; HUMANS; LITHIUM; MONOAMINE OXIDASE INHIBITORS; PINDOLOL; SEROTONIN UPTAKE INHIBITORS; TRIIODOTHYRONINE; TRYPTOPHAN;

EID: 0034050052     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (100)

1. Joffe RT, Singer W, Levitt AJ, et al. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-393
2. Stein G, Bernadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses Br J Psychiatry 1993;162:634-640
3. Delgado PL, Price LH, Charney DS, et al. Efficacy of fluvoxamine in treatment-refractory depression. J Affect Disord 1988;15:55-60
4. de Montigny C, Cournoyer G, Morissete R, et al. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 1983;40:1327-1334
5. Coppen A, Shaw DM, Farrell JP. Potentiation of the antidepressive effect of a monoamine-oxidase inhibitor by tryptophan. Lancet 1963;2:79-81
6. Pare CMB. Potentiation of monoamine-oxidase inhibitors by tryptophan. Lancet 1963;2:527-528
7. Glassman AH, Platman SR, Potentiation of a monoamine oxidase inhibitor by tryptophan. J Psychiatry Res 1969;7:83-88
8. Ayuso Gutierrez JL, Alino JJ. Tryptophan and an MAOI (nialamide) in the treatment of depression: a double-blind study. Int Pharmacopsychiatry 1971;6:92-97
9. Shaw DM, Johnson AL, MacSweeney DA. Tricyclic antidepressants and tryptophan in unipolar affective disorder. Lancet 1972;2:1245
10. Walinder J, Skott A, Carlsson A, et al. Potentiation of the antidepressant action of clomipramine by tryptophan. Arch Gen Psychiatry 1976;33: 1384-1389
11. Thomson J, Rankin H, Ashcroft GW, et al. The treatment of depression in general practice: a comparison of L-tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med 1982; 12:741-751
12. Walinder J, Carlsson A, Persson R. 5-HT reuptake inhibitors plus tryptophan in endogenous depression. Acta Psychiatr Scand 1981;63:179-190
13. Steiner W, Fontaine R. Toxic reaction following the combined administration of fluoxetine and L-tryptophan: 5 case reports. Biol Psychiatry 1986; 21:1067-1071
14. Fawcett J, Sjiomopoulos V. Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression. Arch Gen Psychiatry 1971;25:247-255
15. Van Kammen DP, Murphy DI. Prediction of imipramine antidepressant response by a one-day d-amphetamine trial. Am J Psychiatry 1978;135: 1179-1184
16. Silberman EK, Reus VI, Jimerson DC, et al. Heterogeneity of amphetamine response in depressed patients. Am J Psychiatry 1981;138: 1302-1307
17. Satel SL, Nelson JC. Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989;50:241-249
18. Gwirtsman HE, Szuba MP, Toren L, et al. The antidepressant response to tricyclics in major depressives is accelerated with adjunctive use of methylphenidate. Psychopharmacol Bull 1994;30:157-164
19. Postolache TT, Rosenthal RN, Hellerstien DJ, et al. Early augmentation of sertraline with methylphenidate [letter]. J Clin Psychiatry 1999;60: 123-124
20. Wharton RN, Perel JM, Dayton PG, et al. A potential clinical use of methylphenidate with tricyclic antidepressants. Am J Psychiatry 1971;127: 55-61
21. Feighner JP, Herbstein J, Damlouji N, Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry 1985; 46:206-209
22. Fawcett J, Kravitz HM, Zajecka JM, et al. CNS stimulant potentiation of monoamine oxidase inhibitors in treatment-refractory depression. J Clin Psychopharmacol 1991;11:127-132
23. Naor S, Talmon Y, Guy N. Combined tricyclic antidepressants and Ritalin in elderly depressives. Harefuah 1992;123:251-252
24. Linet LS. Treatment of refractory depression with a combination of fluoxetine and d-amphetamine. Am J Psychiatry 1989;146:803-804
25. Metz A, Shader RI. Combination of fluoxetine with pemoline in major depressive disorder. Int Clin Psychopharmacol 1991;6:93-96
26. Stoll AL, Pillay SS, Diamond L, et al. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry 1996;57:72-76
27. Prange AJ Jr, Wilson IC, Rabon AM, et al. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry 1969;126: 457-469
28. Goodwin FK, Prange AJ, Post RM, et al. Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders. Am J Psychiatry 1982;139:34-38
29. Thase ME, Kupfer DJ, Jarrett DB. Treatment of imipramine-resistant recurrent depression, I: an open clinical trial of adjunctive L-triiodothyronine. J Clin Psychiatry 1989;50:385-388
30. 3 to potentiate tricyclic antidepressant response. J Affect Disord 1987;13:267-272
31. Joffe RT, Singer W. A comparison of triiodothyronine and thyroxine in the potentiation of tricyclic antidepressants. Psychiatry Res 1990;32:241-251
32. Joffe RT. Triiodothyronine potentiation of fluoxetine in depressed patients. Can J Psychiatry 1992;37:48-50
33. Lingaerde O, Edlund AH, Gormsen CA, et al. The effect of lithium carbonate in combination with tricyclic antidepressants in endogenous depression. Acta Psychiatr Scand 1974;50:233-242
34. Ebert D, Jaspert A, Murata H, et al. Initial lithium augmentation improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients. Psychopharmacology 1995;118:223-225
35. Cappiello AC, McDougle CJ, Delgado PL, et al. Lithium plus desipramine versus desipramine alone in the treatment of severe major depression: a preliminary study. Int Clin Psychopharmacol 1998;13:191-198
36. de Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiatry 1981;138:252-256
37. Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentalion of antidepressant treatment: an effective prescription for treatmentrefractory depression. Arch Gen Psychiatry 1983;40:1335-1342
38. Cournoyer G, de Montigny D, Ouellette J, et al. Lithium addition in tricyclic-resistant unipolar depression: a placebo-controlled study. Presented at the 14th Collegium Internationale Neuro-Psychopharmacologicum; June 19-23, 1984; Florence, Italy
39. Schopf J, Baumann P, Lemarchand T, et al. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study. Pharmacopsychiatry 1989;22:183-187
40. Katona CLE, Abou-Saleh MT, Harrison DA, et al. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 1995;166:80-86
41. Bauman P, Nil R, Souche A, et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996;16:307-314
42. Price LH, Charney DS, Heninger G. Variability of response to lithium augmentation in refractory depression. Am J Psychiatry 1986;143:1387-1392
43. Thase ME, Kupfer DJ, Frank E, et al. Treatment of imipramine-resistant recurrent depression, II: an open clinical trial of lithium augmentation. J Clin Psychiatry 1989;50:413-417
44. Nelson JC, Mazure C. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 1986;143:363-366
45. de Montigny C, Aghajanian GK. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978;202:1303-1306
46. Goldberg RS, Thornton WE. Combined tricyclic-MAOI therapy for refractory depression: a review, with guidelines for appropriate usage. J Clin Pharmacol 1978;18:143-147
47. Pare CM, Al Mousawi MA, Sandler M, et al. Attempts to attenuate the "cheese effect": combined drug therapy in depressive illness. J Affect Disord 1985;9:137-141
48. Lader M. Combined use of tricyclic antidepressants and monoamine oxidase inhibitors. J Clin Psychiatry 1983;44(9, sec 2):20-24
49. Devlin MJ, Walsh BT. Use of monoamine oxidase inhibitors in refractory depression. In: Tasman A, Goldfinger SM, Kaufman CA, eds, American Psychiatric Press Review of Psychiatry, vol 9. Washington, DC: American Psychiatric Press; 1990:74-90
50. Young JPR, Lader MH, Hughes WC. Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients. BMJ 1979;2:1315-1317
51. Jacobsen FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry 1991;52:217-220
52. Bakish D. Fluoxetine potentiation by buspirone: three case histories. Can J Psychiatry 1991;36:749-750
53. Joffe RT, Schuller DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 1993;54: 269-271
54. Dimitriou EC, Dimitriou CE. Buspirone augmentation of antidepressant therapy. J Clin Psychopharmacol 1998;18:465-469
55. Bouwer C, Stein DJ. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression. S Afr Med J 1997;87:534-537
56. Fischer P, Tauscher J, Kufferle B, et al. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression. Int Clin Psychopharmacol 1998;13:83-86
57. Landen M, Bjorling G, Agren H, et al. A randomized, double-blind, placebo-controlled trial of buspirone in combination with an SSRI in patients with treatment-refractory depression. J Clin Psychiatry 1998;59:664-668
58. Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry 1989;50:447-449
59. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992;161:562-565
60. Zajecka JM, Jeffriess H, Fawcett J. The efficacy of fluoxetine combined with a heterocyclic antidepressant in treatment-resistant depression: a respective analysis. J Clin Psychiatry 1995;56:338-343
61. Nelson JC, Mazure CM, Bowers MB, et al. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
62. Nelson JC, Mazure C, Bowers MB Jr, et al. Synergistic effects of fluoxetine and desipramine: a prospective study. Presented at the 21st Collegium Internationale Neuro-Psychopharmacologicum; June 12-16, 1998; Glasgow, Scotland
63. Fava M, Rosenbaum JF, Grossbard SJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double blind, controlled study. Am J Psychiatry 1994;151:1372-1374
64. Nelson JC, Price LH. Lithium or desipramine augmentation of fluoxetine treatment. Am J Psychiatry 1995;152:152-159
65. Nelson JC, Jatlow P, Quinlan DM, et al. Desipramine plasma concentrations and antidepressant response. Arch Gen Psychiatry 1982;39: 1419-1422
66. Preskorn SH, Beber JH, Faul JC, et al. Serious adverse effects of combining fluoxetine and tricyclic antidepressants [letter]. Am J Psychiatry 1990; 147:532
67. Boyer WF, Feighner JP. The combined use of fluoxetine and bupropion. Presented at the 1995 annual meeting of the American Psychiatric Association; May 27, 1995: Miami, Fla
68. Bodkin JA, Lasser RA, Wines JD Jr, et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997;58:137-145
69. Spier SP. Use of bupropion with SSRIs and venlafaxine. Depress Anxiety 1998;7:73-75
70. Marshall RD, Johannet CM, Collins PY, et al. Bupropion and sertraline combination treatment in refractory depression. J Psychopharmacol 1995; 9:284-286
71. Marshall RD, Leibowitz MR. Paroxetine/bupropion combination treatment for refractory depression. J Clin Psychopharmacol 1996;16:80-81
72. Fredman SJ, Rosenbaum JF, Fava M, et al. How often do psychiatrists raise the dose when SSRIs do not work? In: New Research Program and Abstracts of the 152nd Annual Meeting of the American Psychiatric Association; May 17, 1999; Washington, DC. Abstract NR128:97
73. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
74. Blier P, de Montigny C, Chaput Y. Modification of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J Clin Psychopharmacol 1987;7:24S-35S
75. Berman RM, Darnell AM, Miller HL, et al. Double-blind placebo-controlled trial of pindolol in depression. In: New Research Program and Abstracts of the 1995 Annual Meeting of the American Psychiatric Association; May 22, 1995; Miami, Fla. Abstract NR104:82
76. Perez V, Gilaberte I, Paries D, et al. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997;349:1594-1597
77. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997;12:81-89
78. Zanardi R, Artigas F, Frarchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997;17:446-450
79. Bordet R, Thomas P, Dupuis B. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. Am J Psychiatry 1998;155: 1346-1351
80. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15:217-222
81. Moreno FA Gelenberg AJ, Bachar K, et al. Pindolol augmentation in treatment-resistant depressed patients. J Clin Psychiatry 1997;58:437-439
82. Perez V, Soler J, Puigdemont D, et al. A double-blind randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Arch Gen Psychiatry 1999;56: 375-379
83. Besson A, Haddjeri N, Debonnel G, et al. Effects of the mirtazapine-paroxetine combination on 5-HT neurotransmission in the rat forebrain [abstract]. Soc Neurosci 1998;23:1225
84. Cappiello A, McDougle C, Malison R, et al. Yohimbine augmentation of fluvoxamine in refractory depression: a single-blind study. Biol Psychiatry 1995;38:765-767
85. Dam J, Ryde L, Svejso J, et al. Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depress on. Pharmacopsychiatry 1998;31:48-54
86. Maes M, Libbrecht I, van Hunsel F, et al. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J Clin Psychopharmacol 1999;19:177-182
87. Carpenter LL, Jocic Z, Hall JM, et al. Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 1999;60:45-49
88. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60: 256-259
89. Lakoski JM, Aghajanian GK. Effects of ketanserin on neuronal responses to serotonin in the prefiontal cortex, lateral geniculate and dorsal raphe nucleus. Neuropharmacology 1985;24:265-273
90. McDougle CJ, Fleischmann RL, Epperson CN, et al. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. J Clin Psychiatry 1995;56:526-528
91. Saxena S, Wang D, Bystritsky A, et al. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306
92. Stein DJ, Bouwer C, Hawkridge S, et al. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122
93. Price LH, Charney DS, Delgado PL, et al. Fenfluramine augmentation in tricyclic-refractory depression. J Clin Psychopharmacol 1990;10:312-317
94. Charney DS, Price LH, Heninger GR. Desipramine-yohimbine combination treatment of refractory depression. Arch Gen Psychiatry 1986;43: 1155-1161
95. Price LH, Charney DS, Heninger GR. Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects. Psychopharmacology (Berl) 1987;92:431-437
96. Oppenheim G, Zohar J. Shapiro B, et al. The role of estrogen in treating resistant depression. In: Zohar J, Belmaker RH, eds. Treating Resistant Depression, New York, NY: PMA Publishing; 1987:357-366
97. Schneider LS, Small GW, Hamilton SH, et al. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry 1997;5:97-106
98. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998;59(suppl 5):51-58
99. Reynolds CF, Frank E, Perel JM, et al. High relapse rate after discontinuation of adjunctive medication for elderly patients with recurrent major depression. Am J Psychiatry 1996;153:1418-1422
100. Wellbutrin [bupropion]. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2000:1301-1304